Matches in Wikidata for { <http://www.wikidata.org/entity/Q60473059> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- Q60473059 description "article scientifique publié en 2016" @default.
- Q60473059 description "im Mai 2016 veröffentlichter wissenschaftlicher Artikel" @default.
- Q60473059 description "wetenschappelijk artikel" @default.
- Q60473059 description "наукова стаття, опублікована в травні 2016" @default.
- Q60473059 name "Safety and efficacy of buparlisib (BKM120) and chemotherapy in advanced, squamous non-small cell lung cancer (sqNSCLC): Results from the phase Ib/II BASALT-2 and BASALT-3 studies" @default.
- Q60473059 name "Safety and efficacy of buparlisib (BKM120) and chemotherapy in advanced, squamous non-small cell lung cancer (sqNSCLC): Results from the phase Ib/II BASALT-2 and BASALT-3 studies" @default.
- Q60473059 type Item @default.
- Q60473059 label "Safety and efficacy of buparlisib (BKM120) and chemotherapy in advanced, squamous non-small cell lung cancer (sqNSCLC): Results from the phase Ib/II BASALT-2 and BASALT-3 studies" @default.
- Q60473059 label "Safety and efficacy of buparlisib (BKM120) and chemotherapy in advanced, squamous non-small cell lung cancer (sqNSCLC): Results from the phase Ib/II BASALT-2 and BASALT-3 studies" @default.
- Q60473059 prefLabel "Safety and efficacy of buparlisib (BKM120) and chemotherapy in advanced, squamous non-small cell lung cancer (sqNSCLC): Results from the phase Ib/II BASALT-2 and BASALT-3 studies" @default.
- Q60473059 prefLabel "Safety and efficacy of buparlisib (BKM120) and chemotherapy in advanced, squamous non-small cell lung cancer (sqNSCLC): Results from the phase Ib/II BASALT-2 and BASALT-3 studies" @default.
- Q60473059 P1433 Q60473059-ECB34CCC-D691-45CB-8715-E03FD3EBDD1C @default.
- Q60473059 P1476 Q60473059-A7AFB5D0-06E8-4D78-8E65-D061F847D455 @default.
- Q60473059 P2093 Q60473059-01011CFF-AD87-43FF-BFC3-76668220318D @default.
- Q60473059 P2093 Q60473059-133A6D03-9865-4653-8593-F0C7041D55B4 @default.
- Q60473059 P2093 Q60473059-1C092A01-9374-498A-804F-95AB28CEB657 @default.
- Q60473059 P2093 Q60473059-2330D344-2856-468A-A153-AD852347FF2E @default.
- Q60473059 P2093 Q60473059-3507CE83-FB24-4459-83C7-7C407460200C @default.
- Q60473059 P2093 Q60473059-3E0EE43B-97B9-4039-82D4-D4D1B628BDAC @default.
- Q60473059 P2093 Q60473059-3EB641A6-5D29-4CB3-888A-4C7FE406D1CE @default.
- Q60473059 P2093 Q60473059-476D1B63-B2F9-455E-B01B-E3CB3D66F5B1 @default.
- Q60473059 P2093 Q60473059-49581EBC-5998-41E9-9419-29F922B27FD0 @default.
- Q60473059 P2093 Q60473059-7A014BA7-CA9A-4F81-8226-9CBDF1F49675 @default.
- Q60473059 P2093 Q60473059-866DCA16-7D1C-49B9-8EF2-83144DFE95D1 @default.
- Q60473059 P2093 Q60473059-91C52090-E38F-40A4-9820-C42E57B1963C @default.
- Q60473059 P2093 Q60473059-D90206D8-3019-4BF6-93E3-75536CA8777E @default.
- Q60473059 P2093 Q60473059-DA82A1FC-DFFC-40A2-B85F-3A048DB5D8F0 @default.
- Q60473059 P2093 Q60473059-EF2DFFD1-0CD5-4CBB-BF16-6839B0790EDC @default.
- Q60473059 P2093 Q60473059-F2A41F55-E5B4-4B9A-A79D-3E83716EEF17 @default.
- Q60473059 P304 Q60473059-B7017F15-6D09-4ECF-95B0-275BB101EDA2 @default.
- Q60473059 P31 Q60473059-EF776769-3C9A-4972-BD2C-DDCDE7C9AC48 @default.
- Q60473059 P356 Q60473059-77EBC1FA-F968-4269-9571-D0861B0C8F9A @default.
- Q60473059 P407 Q60473059-70975A00-C9D9-44D4-B3B8-FECEDA2A4CB5 @default.
- Q60473059 P433 Q60473059-49E82D8D-93A2-469B-8598-5DA5136F959A @default.
- Q60473059 P478 Q60473059-5283F6A9-2419-4870-A729-BD01515A9C85 @default.
- Q60473059 P50 Q60473059-6FA781A9-DC0A-4D45-831E-CB4502FC98B1 @default.
- Q60473059 P50 Q60473059-83D15E14-442E-4749-9064-74E4D86E097A @default.
- Q60473059 P50 Q60473059-8F62A335-82AA-4B9B-8EAD-DC8254F188A6 @default.
- Q60473059 P577 Q60473059-69167739-7EAF-488F-9B97-9394187AA118 @default.
- Q60473059 P921 Q60473059-6A352E20-0FB5-44A2-9864-18AF26CF4F71 @default.
- Q60473059 P356 JCO.2016.34.15_SUPPL.E20522 @default.
- Q60473059 P1433 Q400292 @default.
- Q60473059 P1476 "Safety and efficacy of buparlisib (BKM120) and chemotherapy in advanced, squamous non-small cell lung cancer (sqNSCLC): Results from the phase Ib/II BASALT-2 and BASALT-3 studies" @default.
- Q60473059 P2093 "Alex A. Adjei" @default.
- Q60473059 P2093 "Arunava Chakravartty" @default.
- Q60473059 P2093 "David Planchard" @default.
- Q60473059 P2093 "Diego Luigi Cortinovis" @default.
- Q60473059 P2093 "Enriqueta Felip" @default.
- Q60473059 P2093 "Eric Scott Schaefer" @default.
- Q60473059 P2093 "Francesco Grossi" @default.
- Q60473059 P2093 "Jaafar Bennouna" @default.
- Q60473059 P2093 "Javier De Castro" @default.
- Q60473059 P2093 "Joan Maier" @default.
- Q60473059 P2093 "Juergen Alt" @default.
- Q60473059 P2093 "Luis Paz-Ares" @default.
- Q60473059 P2093 "Marie Chol" @default.
- Q60473059 P2093 "Natasha B. Leighl" @default.
- Q60473059 P2093 "Paola Aimone" @default.
- Q60473059 P2093 "Tommaso Martino De Pas" @default.
- Q60473059 P304 "e20522-e20522" @default.
- Q60473059 P31 Q13442814 @default.
- Q60473059 P356 "10.1200/JCO.2016.34.15_SUPPL.E20522" @default.
- Q60473059 P407 Q1860 @default.
- Q60473059 P433 "15_suppl" @default.
- Q60473059 P478 "34" @default.
- Q60473059 P50 Q37828902 @default.
- Q60473059 P50 Q57027992 @default.
- Q60473059 P50 Q90124509 @default.
- Q60473059 P577 "2016-05-20T00:00:00Z" @default.
- Q60473059 P921 Q974135 @default.